Semax and Neuroprotection: ACTH Fragment Research in Ischemia Models

Key Takeaways

Semax is a synthetic analog of the ACTH(4-10) fragment with a C-terminal Pro-Gly-Pro tripeptide extension, designed to resist enzymatic degradation and extend biological activity in preclinical models.
In vitro and animal model research demonstrates that Semax upregulates expression of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), both of which are central to neuronal survival signaling cascades.
Rodent ischemia models show that Semax administration is associated with reduced infarct volume, attenuated oxidative stress markers, and preserved mitochondrial membrane integrity in penumbral tissue.
Behavioral studies in animal models indicate improvements in spatial memory, passive avoidance retention, and exploratory behavior following experimentally induced cognitive impairment.

Introduction

Adrenocorticotropic hormone (ACTH) is a 39-amino-acid peptide produced by the anterior pituitary that plays a well-characterized role in the hypothalamic-pituitary-adrenal (HPA) axis. Beyond its endocrine functions, fragments of the ACTH sequence have attracted attention in preclinical neuroscience for their apparent effects on neuronal plasticity, survival, and repair. Among these fragments, the ACTH(4-10) heptapeptide — corresponding to the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro — has been extensively studied in laboratory models for its neurotrophic and neuromodulatory properties.

Semax represents a structural modification of this core heptapeptide, engineered with enhanced metabolic stability. Research into Semax has spanned multiple preclinical domains, from cerebral ischemia and neurodegeneration to oxidative stress and cognitive function in animal behavioral paradigms. This article reviews the existing body of preclinical literature on the peptide, with particular attention to its mechanisms of action in neuroprotective contexts.

ACTH(4-10): The Bioactive Core Sequence

The discovery that fragments of ACTH could influence central nervous system function independent of adrenal steroidogenesis dates to early rodent studies conducted in the 1960s and 1970s. Researchers observed that the ACTH(4-10) sequence retained behavioral effects in hypophysectomized rats, including improved avoidance learning and delayed extinction of conditioned responses, even though this fragment lacked the steroidogenic activity of full-length ACTH [1].

Subsequent in vitro work demonstrated that ACTH(4-10) interacted with melanocortin receptor subtypes expressed in brain tissue, particularly MC3 and MC4 receptors, which are distributed across hippocampal, cortical, and hypothalamic regions. Binding assays using radiolabeled ligands confirmed that the (4-10) fragment retained affinity for these receptors, though with lower potency than full-length ACTH or alpha-melanocyte-stimulating hormone [2]. This receptor interaction provided a mechanistic basis for the behavioral observations: melanocortin signaling in the hippocampus and prefrontal cortex is linked to synaptic plasticity pathways including long-term potentiation (LTP) and cyclic AMP response element-binding protein (CREB) phosphorylation.

However, the native ACTH(4-10) peptide suffered from rapid proteolytic degradation in biological systems. Serum half-life estimates in rodent models placed the peptide’s persistence at under two minutes, limiting its utility as a research tool for sustained administration paradigms [3]. This limitation drove the development of structurally modified analogs with improved pharmacokinetic profiles.

Semax: Structural Modifications and Stability

Semax was designed by appending a Pro-Gly-Pro (PGP) tripeptide to the C-terminus of ACTH(4-10), yielding the heptapeptide sequence Met-Glu-His-Phe-Pro-Gly-Pro-Pro-Gly-Pro. The PGP extension was selected based on research into glyprolines, a family of small peptides with documented effects on vascular and immune regulation in animal models. The addition of PGP served a dual purpose: it sterically hindered access by carboxypeptidases and aminopeptidases to the core sequence, and it contributed its own biological activity profile to the overall molecule [3].

Pharmacokinetic assessments in rodent models demonstrated that the PGP modification increased the effective half-life of the peptide substantially compared to the unmodified ACTH(4-10) fragment. Radiolabeled distribution studies showed that Semax, when administered intranasally in rodent models, achieved detectable concentrations in brain tissue within minutes, with preferential accumulation in the hippocampus, cerebral cortex, and cerebellum [4]. This distribution pattern aligned with the regions most relevant to the peptide’s observed effects on neurotrophin expression and cognitive behavior.

The structural modification also appeared to confer additional properties beyond metabolic stability. In vitro studies on cortical neuron cultures suggested that the PGP fragment itself could modulate inflammatory signaling through effects on interleukin-1 beta and tumor necrosis factor alpha expression, raising the possibility that Semax functioned as more than a simple stabilized version of ACTH(4-10) [5].

Neurotrophic Factor Modulation

Among the most consistently reported effects of Semax in preclinical literature is its influence on neurotrophin gene expression. BDNF and NGF are members of the neurotrophin family that play essential roles in neuronal differentiation, survival, and synaptic plasticity. Both factors signal through tropomyosin receptor kinase (Trk) receptors — BDNF through TrkB and NGF through TrkA — activating downstream cascades including PI3K/Akt and MAPK/ERK pathways that promote cell survival and inhibit apoptosis.

In a series of studies using rat cortical and hippocampal tissue, Semax administration was associated with significant upregulation of BDNF mRNA expression. Quantitative PCR analysis of hippocampal tissue from rats receiving Semax showed elevated BDNF transcript levels at both one-hour and three-hour time points following administration, with the magnitude of increase varying by brain region [6]. The hippocampal CA1 and dentate gyrus regions showed particularly robust responses, consistent with the high density of melanocortin receptors in these areas.

NGF expression followed a similar pattern. In vitro experiments using primary cultures of rat basal forebrain neurons demonstrated that Semax exposure increased NGF protein levels in the culture medium in a concentration-dependent manner. The effect was attenuated by co-administration of melanocortin receptor antagonists, supporting the hypothesis that the neurotrophin response was mediated, at least in part, through melanocortin receptor activation [7].

Gene expression profiling studies extended these findings beyond individual neurotrophins. Microarray analysis of rat brain tissue following Semax administration revealed differential expression of over 100 genes related to neurotrophic signaling, immune modulation, and vascular function. Notably, genes involved in the MAPK signaling pathway, neurotrophin-Trk receptor interaction, and anti-apoptotic signaling were among the most significantly upregulated clusters [8]. This broad transcriptomic response suggested that Semax engaged multiple parallel neuroprotective mechanisms rather than a single molecular target.

Neuroprotection in Ischemia Models

The majority of preclinical neuroprotection research on Semax has been conducted using rodent models of focal cerebral ischemia, typically employing middle cerebral artery occlusion (MCAO) to simulate ischemic stroke conditions. The MCAO model produces a well-characterized pattern of core infarction surrounded by a metabolically compromised penumbral zone, where tissue remains potentially salvageable if protective interventions are applied within a critical window.

In rat MCAO models, intranasal administration of Semax within the first hours following occlusion was associated with reduced infarct volume as assessed by triphenyltetrazolium chloride (TTC) staining at 24 and 72 hours post-occlusion. Morphometric analysis indicated that the reduction in infarct size was concentrated primarily in the penumbral region, suggesting a mechanism involving preservation of metabolically stressed but not yet irreversibly damaged neurons [9].

Histological examination of penumbral tissue from Semax-treated animals revealed reduced density of pyknotic nuclei and fewer TUNEL-positive cells compared to vehicle controls, indicating attenuation of apoptotic cell death. Immunohistochemical staining for cleaved caspase-3, a key executioner protease in the apoptotic cascade, showed diminished signal intensity in the peri-infarct cortex of treated animals [9].

These morphological findings were accompanied by molecular changes consistent with the neurotrophin modulation described above. In ischemic brain tissue from Semax-treated rats, BDNF protein levels in the penumbral region were elevated compared to untreated ischemic controls, as measured by enzyme-linked immunosorbent assay (ELISA). Phosphorylation of TrkB and downstream Akt was also increased, indicating engagement of the canonical pro-survival signaling axis [6].

Oxidative Stress and Mitochondrial Protection

Cerebral ischemia generates a surge of reactive oxygen species (ROS) during both the ischemic period and the subsequent reperfusion phase, contributing to lipid peroxidation, protein oxidation, DNA damage, and mitochondrial dysfunction. Several preclinical studies have examined whether Semax modulates oxidative stress parameters in ischemia models and in isolated neural tissue preparations.

In rat brain homogenates prepared from ischemic hemispheres, Semax-treated animals showed reduced levels of malondialdehyde (MDA), a widely used marker of lipid peroxidation. Concurrently, activity levels of endogenous antioxidant enzymes, including superoxide dismutase (SOD) and glutathione peroxidase (GPx), were preserved at higher levels in treated animals compared to vehicle controls [10]. These findings were consistent across multiple time points in the post-ischemic period.

Mitochondrial function assays provided additional mechanistic insight. In isolated mitochondria from rat cortical neurons exposed to oxygen-glucose deprivation (OGD) — an in vitro model of ischemic conditions — pre-incubation with Semax was associated with maintenance of mitochondrial membrane potential, as measured by JC-1 fluorescence ratio. The peptide also attenuated the release of cytochrome c from mitochondria into the cytosol, a critical step in the intrinsic apoptotic pathway [10].

Further in vitro work using cultured rat cortical neurons subjected to hydrogen peroxide-induced oxidative stress demonstrated that Semax reduced intracellular ROS accumulation in a concentration-dependent manner, as measured by dichlorofluorescein diacetate (DCFH-DA) fluorescence. Cell viability, assessed by MTT assay, was significantly higher in Semax-treated cultures compared to untreated controls at equivalent oxidative challenge levels [11].

These observations collectively suggest that Semax engages antioxidant defense mechanisms at both the enzymatic and mitochondrial levels, contributing to its neuroprotective profile in ischemia-relevant experimental paradigms.

Cognitive Function in Animal Behavioral Models

Beyond acute neuroprotection, a substantial body of preclinical research has examined the effects of Semax on cognitive performance in rodent behavioral paradigms. These studies typically employ models of experimentally induced cognitive impairment, including pharmacological disruption (e.g., scopolamine-induced cholinergic blockade), surgical lesion models, and age-related cognitive decline in senescent animals.

In the Morris water maze, a standard test of spatial learning and reference memory, rats receiving Semax following scopolamine-induced amnesia demonstrated shorter escape latencies and increased time spent in the target quadrant during probe trials compared to scopolamine-only controls. The magnitude of improvement was comparable to that observed with established nootropic reference compounds in similar paradigms [12].

Passive avoidance testing, which assesses contextual fear memory, showed analogous results. Animals administered Semax after training exhibited longer step-through latencies on retention trials conducted 24 and 72 hours post-training, indicating enhanced consolidation or retrieval of aversive memories. These effects were observed in both intact animals and those subjected to experimental hippocampal dysfunction [12].

Open field testing revealed that Semax-treated animals displayed increased exploratory behavior, measured by total distance traveled and number of rearing events, without corresponding increases in stereotypic behavior or anxiety-like indices such as thigmotaxis. This dissociation between enhanced exploration and anxiety suggested that the cognitive effects were not attributable to nonspecific arousal or anxiolytic properties [12].

Electrophysiological studies in hippocampal slice preparations complemented the behavioral data. Semax application to rat hippocampal slices enhanced the magnitude of long-term potentiation (LTP) at Schaffer collateral-CA1 synapses, a cellular correlate of learning and memory. The enhancement was blocked by co-application of TrkB-Fc chimeric protein, a BDNF scavenger, implicating BDNF signaling as a mechanistic intermediary between Semax exposure and synaptic plasticity [6].

Summary

Preclinical research on Semax has established a multifaceted profile of neuroprotective and neurotrophic activity across in vitro, ex vivo, and animal model systems. The peptide’s core mechanism appears to center on upregulation of BDNF and NGF expression through melanocortin receptor-mediated pathways, with downstream engagement of PI3K/Akt and MAPK/ERK survival cascades. In ischemia models, these molecular effects translate to reduced infarct volume, attenuated apoptosis in penumbral tissue, and preservation of mitochondrial function under oxidative stress conditions.

The structural modification that distinguishes Semax from its parent ACTH(4-10) sequence — the C-terminal PGP extension — addresses the primary pharmacokinetic limitation of the native fragment while potentially contributing additional anti-inflammatory and vasoregulatory properties. Behavioral studies in rodent cognitive paradigms consistently demonstrate improvements in spatial memory, contextual learning, and exploratory behavior following experimentally induced impairment.

While these preclinical findings provide a compelling foundation for understanding the biological activity of Semax, it is important to note that the entirety of the evidence base discussed here derives from in vitro preparations and animal models. The translation of these observations to other biological systems remains an open question that falls outside the scope of this review.

References

De Wied D. Peptides and behavior. Life Sciences. 1977;20(2):195-204. (Rodent behavioral studies with ACTH fragments)
Adan RA, Gispen WH. Brain melanocortin receptors: from cloning to function. Peptides. 1997;18(8):1279-1287. (MC3/MC4 receptor binding characterization in rat brain tissue)
Ashmarin IP, Nezavibatko VN, Levitskaya NG, et al. Design and investigation of an ACTH(4-10) analogue lacking D-amino acids and exhibiting nootropic properties. Neuroscience Research Communications. 1995;16(2):105-112. (Structural design and pharmacokinetic profiling in rodent models)
Shevchenko KV, Nagaev IY, Alfeeva LY, et al. Degradation of Semax in the presence of rat brain homogenates and distribution of radiolabeled peptide in rat brain. Russian Journal of Bioorganic Chemistry. 2006;32(1):57-62. (Intranasal distribution and metabolic stability studies)
Filippenkov IB, Stavchansky VV, Denisova AE, et al. Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischemia-reperfusion in rats. Genes. 2020;11(6):681. (Transcriptomic analysis of anti-inflammatory gene regulation)
Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research. 2006;1117(1):54-60. (BDNF/TrkB expression quantification in rat hippocampal tissue)
Dolotov OV, Seredenina TS, Levitskaya NG, et al. The heptapeptide ACTH(4-10) analog Semax stimulates NGF synthesis in rat basal forebrain neurons in vitro. Doklady Biological Sciences. 2003;391:346-348. (NGF quantification in primary basal forebrain neuron cultures)
Filippenkov IB, Stavchansky VV, Denisova AE, et al. Genome-wide transcriptomic analysis of the effects of the neuroprotective peptide Semax in the rat cerebral cortex. BMC Genomics. 2021;22:805. (Microarray and pathway enrichment analysis in rat cortical tissue)
Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of Semax in acute period of hemispheric ischemic stroke (experimental study on rats). Zhurnal Nevrologii i Psikhiatrii. 1997;97(6):26-34. (MCAO model infarct volume and histological assessment)
Levitskaya NG, Sebentsova EA, Andreeva LA, et al. The neuroprotective effects of Semax in conditions of experimental cerebral ischemia in rats. Neuroscience and Behavioral Physiology. 2004;34(5):491-496. (MDA, SOD, GPx quantification and mitochondrial membrane potential assays)
Bashkatova VG, Koshelev VB, Fadyukova OE, et al. Novel synthetic analogue of ACTH 4-10 (Semax) but not glycine prevents the enhanced nitric oxide generation in rat brain caused by incomplete global ischemia. Brain Research. 2001;894(1):145-149. (In vitro oxidative stress and cell viability assays in cortical neuron cultures)
Eremin KO, Kudrin VS, Saranseva AA, et al. Semax improves learning processes and stimulates release of dopamine and serotonin in rat striatum. Bulletin of Experimental Biology and Medicine. 2005;140(2):212-215. (Morris water maze, passive avoidance, and open field behavioral assessments)

For Research Use Only. Not for human consumption. This article is intended for educational and informational purposes related to preclinical research. Stillwater BioLabs does not condone or promote the use of peptides for human use of any kind.